Value of reverse transcription, polymerase chain reaction assay in pathological stage T3N0 prostate cancer

Prostate

Volumn 44, Issue 3, 2000, Pages 210-218

  Okegawa, Takatsugu ^a,b   Noda, Haruhisa ^a   Kato, Moriaki ^a   Miyata, Akiomi ^a   Nutahara, Kikuo ^a   Higashihara, Eiji ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biochemical recurrence; Polymerase chain reaction; Prostate cancer; Prostate specific antigen; Prostate specific membrane antigen

Indexed keywords

COMPLEMENTARY DNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; ANTIGENS, SURFACE; BIOPSY, NEEDLE; CARBOXYPEPTIDASES; DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; FOLLOW-UP STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SEQUENCE ANALYSIS, DNA;

EID: 0034256019     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000801)44:3<210::AID-PROS5>3.0.CO;2-U     Document Type: Article

References (34)

1. Stein A, deKernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-946.
2. Catalona WJ, Smith DS. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
3. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-138.
4. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-292.
5. Pound CR, Partin AW, Epstein JI, Walsh PC. PSA following anatomical radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
7. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 1992;52:6110-6112.
8. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994;12:2634-2639.
9. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R. Molecular staging of prostate cancer with the use of an enhanced reverse transcription polymerase chain reaction assay. Urology 1994;43: 765-775.
10. Israeli RS, Miller WH, Su SL, Samadi DS, Powell CT, Heston WD, Wise GJ, Fair WR. Sensitive detection of prostatic hematogenous dissemination using prostate specific antigen (PSA) and prostate membrane antigen (PSM) derived primers in the polymerase chain reaction. J Urol 1995;153:573-577.
11. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, McMahon D, Benson MC, Katz AE. Molecular staging of prostate cancer 16. A comparison of the application of an enhanced reverse transcription polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-1378.
12. Loric S, Dumas F, Eschwege P, Blanchet P, Benoit G, Jardin A, Lacour B. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcriptase polymerase chain reaction assay based on prostate specific membrane antigen. Clin Chem 1995;41:1698-1704.
13. Zhang Y, Zippe CD, van Lente F, Klein EA, Gupta MK. Combined nested reverse transcription PCR assay for prostate specific antigen and prostate specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 1997;3:1215-1220.
14. Grasso YZ, Gupta MK, Levin HS, Zippe CD, Klein EA. Combined nested RT-PCR assay for prostate specific antigen and prostate specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998;58:1456-1459.
15. Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorety F, Figlin RA, Pang S, deKernion J, Belldegrun A. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-1566.
16. Ignatoff JM, Oefelein MG, Watkin W, Chmiel JS, Kaul KL. Prostate specific antigen transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol 1997;158: 1870-1875.
17. Okegawa T, Yoshioka J, Morita R, Nutahara K, Higashihara E. Molecular staging of prostatic cancer: comparison of the nested reverse transcriptase polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. Int J Urol 1998;5:349-356.
18. Okegawa T, Nutahara K, Higashihara E. Preoperative nested reverse transcription polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence following radical prostatectomy. Br J Urol 1999;84:112-117.
19. Ellis WJ, Vessella RL, Corey E, Arfman EW, Oswin MM, Melchior S, Lange PH. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998;159:1134-1138.
20. Oefelein MG, Ignatoff JM, Clemens JQ, Watkin W, Kaul KL. Clinical and molecular followup after radical retropubic prostatectomy. J Urol 1999;162:307-311.
21. Olsson CA, de Vries GM, Raffo A, Benson MC, O'Toole K, Cao Y, Buttyan RE, Katz AE. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy: molecular staging of prostate cancer. J Urol 1996;155:1557-1562.
22. Ghossein RA, Rosai J, Scher HI, Seiden M, Zhang ZF, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997;50:100-105.
23. Gao CL, Maheshwari S, Dean RC, Tatum L, Mooneyhan R, Connelly RR, McLead DG, Srivastava S, Moul JW. Blinded evaluation of reverse transcriptase polymerase-chain reaction (RT-PCR) prostate specific antigen (PSA) peripheral blood assay for molecular staging of prostate cancer. Urology 1999;53:714-721.
24. Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997;15:3451-3457.
25. Gao CL, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLead DG, Srivastava S, Moul JW. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 1999;161:1070-1076.
26. Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, Fujihiro S, Kawamura T, Komeda H, Horie M. Detection of micrometastatic prostate cancer cells in lymph nodes reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53: 5350-5354.
27. Ferrari AC, Stone NN, Eyler JN, Gao M, Mandeli J, Unger P, Gallagher RE, Stock R. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. J Natl Cancer Inst 1997;89:1498-1504.
28. Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Dollow KC, Traish A, Moreland RB. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study. Urology 1996;47:370-375.
29. International Union Against Cancer. TNM classification of malignant tumours. Urological tumours: prostate. 5th ed. New York: Wiley-Liss; 1997. p 170-173.
30. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, Lo R, Palmer K, Shinohara K, Spaulding JT. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205-212.
31. Partin AW, Yoo Y, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
32. Stone NN, Stock RG, Unger P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154:1392-1396.
33. Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen SC, Toung LL, Taylor CR, Skinner DG, Lieskovsky G, Cote RT. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 1995;154:474-478.
34. Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 1995;55:2640-2644.